{
    "clinical_study": {
        "@rank": "95696", 
        "arm_group": [
            {
                "arm_group_label": "Aripiprazole", 
                "arm_group_type": "Experimental", 
                "description": "Aripiprazole arm,5mg/pill,10mg/day.last12weeks."
            }, 
            {
                "arm_group_label": "Sugar pill", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo arm,5mg/pill,10mg/day,last12weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "Methamphetamine  substance use is common worldwide. No approved pharmacologic treatments for\n      methamphetamine dependence exist. Aripiprazole are Second generation antipsychotics\uff0cbut have\n      different pharmacological effects of   neurotransmitters.To determine whether mirtazapine\n      would reduce methamphetamine use among mehtamphetamine addicts."
        }, 
        "brief_title": "An Study of Aripiprazole in the Treatment of Methamphetamine Dependence", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Methamphetamine Dependence", 
        "detailed_description": {
            "textblock": "Methods:A Multiple-Center, Randomized, Double-Blind."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients,Diagnostic and Statistical Manual of Mental Disorders 4thed. (DSM-IV)\n             criteria for Methamphetamine dependence.\n\n          2. Must sign a Information consent form.\n\n          3. Required to provide detailed address and phone number\n\n        Exclusion Criteria:\n\n          1. Serious organic disease.\n\n          2. Suicide ideation or hurt others.\n\n          3. Taking antipsychotic within two weeks before.\n\n          4. drug allergy to  Risperidone or Aripiprazole.\n\n          5. pregnancy and breastfeeding women."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01813656", 
            "org_study_id": "100000-068942"
        }, 
        "intervention": [
            {
                "arm_group_label": "Aripiprazole", 
                "description": "Aripiprazole group,5mg/pill,10mg/day non-forced titration method,last 12weeks", 
                "intervention_name": "Aripiprazole", 
                "intervention_type": "Drug", 
                "other_name": "Aopai H20041507"
            }, 
            {
                "arm_group_label": "Sugar pill", 
                "description": "placebo group,5mg/pill,10mg/day non-forced titration method,last 12 weeks", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug", 
                "other_name": "placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Methamphetamine", 
                "Aripiprazole"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Methamphetamine-Associated Psychosis", 
            "Aripiprazole"
        ], 
        "lastchanged_date": "March 27, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Changsha", 
                    "country": "China", 
                    "state": "Hunan", 
                    "zip": "410011"
                }, 
                "name": "The Second Xiangya Hospital of Central University"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multiple-Center, Randomized, Double-Blind Study of Aripiprazole for Treatment of Methamphetamine Dependence", 
        "overall_official": {
            "affiliation": "Central South University", 
            "last_name": "Wei Hao, MD., Ph.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": [
                "China: Ethics Committee", 
                "China: National Natural Science Foundation", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "methamphetamine-positive urine test results,self-reports of substance use", 
            "measure": "abstinent time of Methamphetamine addict", 
            "safety_issue": "Yes", 
            "time_frame": "up to 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01813656"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Central South University", 
            "investigator_full_name": "Wei Hao", 
            "investigator_title": "The Second Xiangya Hospital of Cental South University", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "use Abnormal Involuntary Movement Scale ,Simpson-Angus Scale and Barnes akathisia Scale", 
            "measure": "number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "up to 3 months"
        }, 
        "source": "Central South University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wei Hao", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013", 
        "why_stopped": "Aripiprazole arm had obvious adverse reactions,especially akathisia."
    }
}